| 03:20a | MOLOGEN AG : Research coverage by MainFirst starts with 'Outperform' recommendation | EQ |
| 03:13a | SECTRA : Dutch university hospital chooses Sectra for digitizing pathology for primary diagnostics | AQ |
| 03:05a | MOLECULIN BIOTECH : Northern Lights Supply Store in Alberta Receives First Inventory in Preparation for Grand Opening | AQ |
| 03:01a | DIXIE BRANDS USA : subsidiary Aceso launches new CBD-infused dissolvable tablets and topical cream targeting broad consumer retail distribution | AQ |
| 03:01a | HCA HOSPITAL AMERICA : Healtre/HealthONE's Swedish Medical Center Announces 2018 Q4 Employee of the Quarter | AQ |
| 03:01a | FSD PHARMA : Receives Standard Processing License | BU |
| 02:09a | JOHNSON & JOHNSON : NHIF strikes deal to buy cancer drug at half price | AQ |
| 02:01a | Motif Bio Conference Call and Webcast | GL |
| 01:36a | IX BIOPHARMA : to sell Chemical Analysis unit for A$12.5m | AQ |
| 01:36a | WILLIAM DEMANT HOLDING A/S : Investor news - William Demant Holding changes name to Demant | AQ |
| 01:35a | SARTORIUS STEDIM BIOTECH SA : Information on Document Availability | EQ |
| 01:33a | MOTIF BIO : reaches deal to reduce repayment burden | AQ |
| 01:33a | LOXO ONCOLOGY : Bayer takes control of Loxo duo as Lilly closes takeover | AQ |
| 01:33a | WILLIAM DEMANT HOLDING A/S : Annual Report 2018 | AQ |
| 01:32a | LOXO ONCOLOGY : Lilly closes $8bn Loxo Oncology acquisition | AQ |
| 01:18a | ROCHE : FDA grants Priority Review to Roche's personalised medicine entrectinib | PU |
| 01:18a | ROCHE : FDA grants priority review to Roche's polatuzumab vedotin in previously treated aggressive lymphoma | PU |
| 01:16a | BASILEA PHARMACEUTICA : reports strong revenue growth and significant pipeline progress for full-year 2018 | AQ |
| 01:04a | ROCHE : FDA grants Priority Review to Roche's personalised medicine entrectinib | GL |
| 01:02a | ROCHE : FDA grants Priority Review to Roche's polatuzumab vedotin in previously treated aggressive lymphoma | GL |
| 01:01a | VISTIN PHARMA ASA : Fourth quarter 2018 financial results | AQ |
| 01:01a | ROCHE : FDA Grants Priority Review to Genentech's Polatuzumab Vedotin in Previously Treated Aggressive Lymphoma | BU |
| 01:01a | MDXHEALTH (R) : MDxHealth Appoints Michael K. McGarrity as CEO | GL |
| 01:01a | ROCHE : FDA Grants Priority Review to Genentech's Personalized Medicine Entrectinib | BU |
| 12:35a | Straumann posts strong Q4, lifting full-year organic revenue growth to 19% as underlying EBITDA margin reaches 30% | TE |
| 12:31a | STRAUMANN : posts strong Q4, lifting full-year organic revenue growth to 19% as underlying EBITDA margin reaches 30% | AQ |
| 02/18 | SSY : expects 33-40% increase in year net | AQ |
| 02/18 | DENTSPLY 24 HOUR DEADLINE ALERT : Approximately 24 Hours Remain; ClaimsFiler Reminds Investors with Losses in Excess Of $100,000 of Deadline in Class Action Lawsuit Against Dentsply Sirona, Inc. - XRAY | BU |
| 02/18 | ALLERGAN 24 HOUR DEADLINE ALERT : Approximately 24 Hours Remain; ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Allergan plc. - AGN | BU |
| 02/18 | PHARMACARE : Dar Al-Shifa Pharmaceuticals (PHARMACARE) discloses preliminary Annual statements of the fiscal year 2018 (Unconsolidated). | AQ |
| 02/18 | MESOBLAST : Final Patient Dosed in Mesoblast P3 Heart Failure Trial | PU |
| 02/18 | ASTER DM HEALTHCARE : launches month-long cancer awareness campaign | AQ |
| 02/18 | MESOBLAST : Newsletter on Advanced and End-Stage Heart Failure | PU |
| 02/18 | FLUOROURACIL (5FU) MARKET IS BOOMING WORLDWIDE : Mayne Pharma, Celon Labs, NPS MedicineWise, Mylan | AQ |
| 02/18 | ANATARA LIFESCIENCES LTD (ASX : ANR) Investor Presentation | AQ |
| 02/18 | ANATARA LIFESCIENCES LTD (ASX : ANR) Half Yearly Report | AQ |
| 02/18 | PATIENT ENGAGEMENT SOFTWARE MARKET – GROWING POPULARITY AND EMERGING TRENDS IN THE INDUSTRY : McKesson, Athenahealth, Allscripts, Healthagen | AQ |
| 02/18 | MAYNE PHARMA : 19/02/2019 Mayne Pharma Announces New Chronic Breathlessness Indication for Kapanol® by TGA | PU |
| 02/18 | PRECIPIO : Provides Corporate Update Shareholder Call | AQ |
| 02/18 | LIVING CELL TECHNOLOGIES : Half Year Report 31 December 2018 | PU |
| 02/18 | ALIMERA SCIENCES : Reports Record Fourth Quarter and 2018 Results | PU |
| 02/18 | ALIMERA SCIENCES : Reports Record Fourth Quarter and 2018 Results | AQ |
| 02/18 | QIAGEN : partners with Ares Genetics to advance global fight against antibiotic-resistant pathogens | BU |
| 02/18 | E-PRESCRIBING MARKET GROWING POPULARITY AND EMERGING TRENDS IN THE INDUSTRY ANALYSIS BY KEY PLAYERS : Cerner, Athenahealth, Allscripts, eClinicalWorks, DrFirst: E-Prescribing Comprehensive Study by Type (Stand-Alone Systems, Integrated Systems), Application (Hospital, Office-based physician), Delivery Mode (Web-based, On-premise/licensed, Cloud-based), Component (Software, Hardware, Services) Players and Region - Global Market Outlook to 2024 | AQ |
| 02/18 | INVENTIVA : Announces Results From Phase IIb Clinical Trial with Lanifibranor in Systemic Sclerosis | AQ |
| 02/18 | ROBBINS ARROYO LLP : Nektar Therapeutics (NKTR) Officials Harmed the Company According to Shareholder Lawsuit | BU |
| 02/18 | VITROLIFE : IVF Devices Market 2019 Strategic Assessments – Cook Medical, CooperSurgical, Thermo Fisher Scientific, Vitrolife, CellCura | AQ |
| 02/18 | NOVARTIS : Gene therapy company doubles plans for RTP jobs after receiving incentives | AQ |
| 02/18 | Pediatric healthcare market is expected to grow swiftly due to increasing technological development with top key players abbott, astrazeneca, glaxosmithkline, merck & co., pfizer, sanofi, perrigo | AQ |
| 02/18 | QUEST DIAGNOSTICS : Names Gabrielle Wolfson Senior Vice President and Chief Information and Digital Officer | PR |
United Kingdom
France
Deutschland
Schweiz (DE)
